Emergence of Daptomycin Resistance in Enterococcus faecium during Daptomycin Therapy
Open Access
- 1 April 2005
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (4), 1664-1665
- https://doi.org/10.1128/aac.49.4.1664-1665.2005
Abstract
Daptomycin is a cyclic lipopeptide antibiotic that has been available in the United States since September 2003. We report a clinical and bacteriological failure of daptomycin therapy for enterococcal bacteremia. Briefly, a 22-year-old man with Hodgkin's lymphoma, subsequent acute myelogenousThis publication has 6 references indexed in Scilit:
- Clinical-Use-Associated Decrease in Susceptibility of Vancomycin-Resistant Enterococcus faecium to Linezolid: a Comparison with Quinupristin-DalfopristinAntimicrobial Agents and Chemotherapy, 2004
- The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure InfectionsClinical Infectious Diseases, 2004
- In VitroActivity of Daptomycin against Vancomycin-Resistant Enterococci ofVarious Van Types and Comparison of Susceptibility TestingMethodsAntimicrobial Agents and Chemotherapy, 2003
- Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetationsDiagnostic Microbiology and Infectious Disease, 2003
- Linezolid-Resistant, Vancomycin-Resistant Enterococcus faecium Infection in Patients without Prior Exposure to LinezolidClinical Infectious Diseases, 2003
- Linezolid resistance in a clinical isolate of Staphylococcus aureusThe Lancet, 2001